Jornal Vascular Brasileiro
https://www.jvascbras.org/article/doi/10.1590/1677-5449.210108
Jornal Vascular Brasileiro
Letter to the Editor

Polymorphism of the CYP2C9 and VKORC1 genes: a comment

Rujittika Mungmunpuntipantip; Viroj Wiwanitkit

Downloads: 0
Views: 37

Abstract

Dear editor,

We would like to share ideas on “Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil.1” Tozato et al. studied polymorphisms of the CYP2C9 and VKORC1 genes, warfarin, and Time in Therapeutic Range (TTR) and concluded that “An association was observed between the polymorphisms and the warfarin doses taken by the patients. However, there was no association with adverse events or the time spent within the therapeutic range in this sample.1” The study drew conclusions that were not supported by its findings. It should only have concluded on the genetic epidemiology of polymorphisms. There are many confounding factors. An important consideration is the effect of other polymorphisms that are not assessed in the present study. Examples of these polymorphisms are CYP4F2 V433M, ABCB1, PROC, EPHX1, and SETD1A.2,3

References

1 Colet C, Botton MR, Schwambach KH, Amador TA, Heineck I. Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil. J Vasc Bras. 2021;20:e20200214. http://dx.doi.org/10.1590/1677-5449.200214. PMid:34104133.

2 Naushad SM, Kutala VK, Hussain T, Alrokayan SA. Pharmacogenetic determinants of warfarin in the Indian population. Pharmacol Rep. 2021. Epub ahead of print. PMid:34106453.

3 Xu Q, Zhang S, Wu C, et al. Genetic associations with stable warfarin dose requirements in Han Chinese patients. J Cardiovasc Pharmacol. 2021;78(1):e105-11. http://dx.doi.org/10.1097/FJC.0000000000001048. PMid:33958549.
 


Submitted date:
06/22/2021

Accepted date:
07/09/2021

614ddb5aa9539518813da7c6 jvb Articles
Links & Downloads

J Vasc Bras

Share this page
Page Sections